Key result
Urotensin II increases CD68+ tumor-associated macrophage infiltration and inflammatory markers in lung adenocarcinoma mice.
Why the study?
The mechanism by which urotensin II promotes lung adenocarcinoma growth through the tumor inflammatory microenvironment was not fully understood.
Does Urotensin II contribute to the formation of the lung adenocarcinoma inflammatory microenvironment in tumor-bearing nude mice?
Does Urotensin II contribute to the formation of the lung adenocarcinoma inflammatory microenvironment in tumor-bearing nude mice?
p-value: p=<0.01
Urotensin II promotes lung adenocarcinoma growth by enhancing the inflammatory microenvironment via the NF-κB pathway, suggesting that UII or UT-R antagonists may have therapeutic potential.
UII effects on tumor microenvironment warrant no practice change; leaves open therapeutic targeting in human lung adenocarcinoma.
Urotensin II (UII), a somatostatin-like cyclic peptide, was originally isolated from the fish urophysis. Our previous study showed that UII stimulates the proliferation of A549 lung adenocarcinoma cells and promotes tumor growth in a nude mouse xenograft model, suggesting that UII may contribute to the pathogenesis of lung adenocarcinoma. In this study, the underlying mechanism for UII to promote lung adenocarcinoma growth was explored by observing the effect of UII on the tumor inflammatory microenvironment in tumor-bearing nude mice. Immunohistochemical analysis showed that UII promoted the infiltration of CD68(+) tumor-associated macrophages (TAMs) in the tumor micro-environment. Enzyme-linked immunosorbent assay (ELISA) demonstrated that UII promoted the release of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and matrix metalloproteinase-9 (MMP-9). Western blot analysis showed that UII promoted the activation of nuclear factor-κB (NF-κB). These findings suggest that the enhanced levels of IL-6, TNF-α and MMP-9 in the tumor microenvironment, which likely resulted from increased activation of NF-κB induced by UII, may be one of the important mechanisms by which UII promotes lung adenocarcinoma growth. These findings imply that antagonists of UII or urotensin II-receptor (UT-R) have potential for the prevention and treatment of lung adenocarcinoma.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2012) studied Lung adenocarcinoma (n=12). Urotensin II vs. Control was evaluated on Infiltration of CD68+ tumor-associated macrophages (TAMs) (p=<0.01). Urotensin II significantly increased the infiltration of CD68+ tumor-associated macrophages and the levels of IL-6, TNF-α, and MMP-9 in the tumor microenvironment of lung adenocarcinoma-bearing mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: